INB-300 / IN8bio - LARVOL DELTA

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting (GlobeNewswire) - "IN8bio, Inc...today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually."

Clinical • Oncology

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 (GlobeNewswire) - "IN8bio...announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell (nsCAR) platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones....The new data presented at AACR included results from proprietary constructs targeting CD33 and/or CD123 for in vitro evaluation against various types of leukemia, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML)....The nsIL3-33mb15 CAR (CD123+CD33+IL-15) enhancement of the gamma delta T cells against leukemia cells demonstrated an average 1.8x increase in tumor killing capability across three AML cell lines (HL-60, KG-1a and MOLM-13), compared to unmodified gamma-delta T cells as measured by a 24-hour cytotoxicity assay."

Preclinical • Acute Myelogenous Leukemia • Chronic Myeloid Leukemia

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024 (GlobeNewswire) - "IN8bio, Inc...today announced the presentation of new preclinical data for its non-signaling gamma-delta T cell based Chimeric Antigen Receptor T cell (CAR-T) platform, INB-300. The data will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, California."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology • Solid Tumor

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals (GlobeNewswire) - "INB-300: Present additional preclinical data demonstrating proof-of-concept for the nsCAR platform targeting CD33 and CD123 at American Association for Cancer Research (AACR) 2024; INB-400: Dose first patient and treat up to 15 patients at multiple sites across the United States in the Phase 2 trial in newly diagnosed GBM; potentially submit IND for allogeneic Phase 1b in relapsed GBM in 2024."

IND • Preclinical • Trial status • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) - "INB-300: Present additional preclinical data demonstrating proof-of-concept for the nsCAR platform targeting CD33 and CD123 at a medical meeting in first half of 2024."

Preclinical • Oncology

IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) - "Upcoming Pipeline Milestones and Events: (i) INB-100: Report updated Phase 1 trial data from leukemia patients undergoing HSCT at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in April 2023; define recommended Phase 2 dose for INB-100; (ii) INB-200: Complete enrollment of Cohort 3 in the Phase 1 trial; report updated data and results with longer-term follow-up at medical meetings throughout 2023; (iii) INB-300: Present additional preclinical data demonstrating proof-of-concept for the nsCAR platform at the American Association of Cancer Research (AACR) Annual Meeting in April 2023."

P1 data • Preclinical • Trial status • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Brain Cancer • Chronic Myeloid Leukemia • CNS Tumor • Glioblastoma • Glioma • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Solid Tumor

IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023 (GlobeNewswire) - "IN8bio...has announced that preclinical data for its gamma-delta CAR-T technology, INB-300, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023....INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving healthy tissue. Data supports the potential for this next-generation CAR-T technology in previously 'undruggable' solid- and liquid-tumor targets."

Preclinical • Oncology • Solid Tumor

IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue (GlobeNewswire) - "IN8bio…announced the ability of its novel non-signaling gamma-delta CAR-T platform (nsCAR) to selectively target leukemic cells while preserving healthy B cells. The findings were presented by Dr. Lawrence Lamb, IN8bio’s Chief Scientific Officer, during a Plenary session…at the 6th CAR-TCR Summit Europe on February 23^rd…However, IN8bio's nsCAR platform uses the innate immune recognition of gamma-delta T cells to distinguish between tumor and healthy tissue, offering a targeted but potentially less toxic approach. In a 48-hour in vitro cytotoxicity experiment, the nsCAR platform demonstrated a greater than 15x difference in killing between leukemic cells and healthy B cells (E:T=2:1, 79.7% versus 5.2%) when both express the CD19 target antigen….‘This powerful approach could be used in indications such as acute myeloid leukemia (AML) and solid tumor cancers…'"

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals (GlobeNewswire) - "Anticipated 2023 Pipeline Goals: INB-100: Report Phase 1 ongoing trial data from leukemia patients undergoing haploidentical stem cell transplantation (HSCT); define maximum tolerated dose for INB-100. INB-200 in GBM: Complete enrollment of Cohort 3 in the Phase 1 trial; report additional data and topline results with longer-term follow-up. INB-300: Present preclinical data demonstrating proof-of-concept of non-signaling CAR (ns-CAR) platform in 1H 2023."

Enrollment status • P1 data • Preclinical • Glioblastoma • Hematological Malignancies • Leukemia • Oncology

[VIRTUAL] Dual chlorotoxin and methylguanine methyltransferase γδ-T cells for drug resistant immunotherapy of glioblastoma multiforme (AACR 2021) - "We have developed a novel approach to the treatment of primary GBM by combining simultaneous intracranial administration of gene-modified γδ T cells and standard temozolomide (TMZ) maintenance chemotherapy. Overall, we were able to generate dCLTX-CAR T cells with resistance to TMZ and showed improved activation and cytotoxicity against GBM cells under TMZ exposure. Our approach of combining the dCLTX-CAR and TMZ resistance will be further validated in animal model experiments and could be a potential candidate for clinical development for GBM."

IO biomarker • Glioblastoma • Oncology • Solid Tumor • CD69 • MGMT • MMP2

IN8bio Demonstrates In Vitro Activity of DeltEx DRI CAR-T Cells Against Glioblastoma Multiforme at AACR (GlobeNewswire) - “IN8bio…announced a presentation demonstrating that INB-300, its preclinical DeltEx drug resistant immunotherapy platform, or DRI, CAR-T candidate has enhanced persistence and cytotoxicity against glioblastoma multiforme (GBM) cells. The poster (abstract #1490), entitled 'Dual chlorotoxin and methylguanine methyltransferase γδ-T cells for drug resistant immunotherapy of Glioblastoma Multiforme,' will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021 on April 10 by Lei Ding, Ph.D., the program’s lead scientist at IN8bio. The in vitro work presented at AACR demonstrates that the DeltEx DRI CAR-T modified cells can bind GBM cell lines and induce cellular activation as well as demonstrate significant cytotoxic killing and persistence.”

Preclinical • CNS Tumor • Glioblastoma • Glioma • Oncology